Mihai Gheorghiade
#91,949
Most Influential Person Now
Mihai Gheorghiade's AcademicInfluence.com Rankings
Mihai Gheorghiademedical Degrees
Medical
#975
World Rank
#1258
Historical Rank
Cardiology
#50
World Rank
#51
Historical Rank
Mihai Gheorghiadephilosophy Degrees
Philosophy
#3389
World Rank
#5493
Historical Rank
Logic
#1127
World Rank
#1791
Historical Rank
Download Badge
Medical Philosophy
Why Is Mihai Gheorghiade Influential?
(Suggest an Edit or Addition)Mihai Gheorghiade's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) (1999) (4830)
- Third universal definition of myocardial infarction. (2012) (4123)
- The effect of digoxin on mortality and morbidity in patients with heart failure. (1997) (2495)
- The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. (2014) (1566)
- Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. (2007) (1532)
- Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. (2006) (1133)
- Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. (2002) (1096)
- Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. (2007) (1041)
- Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (2005) (966)
- Third universal definition of myocardial infarction. (2012) (921)
- Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007) (818)
- Chronic heart failure in the United States: a manifestation of coronary artery disease. (1998) (797)
- Third universal definition of myocardial infarction. (2012) (751)
- Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. (1993) (750)
- Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. (2006) (738)
- Acute Heart Failure Syndromes: Current State and Framework for Future Research (2005) (731)
- Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. (2006) (723)
- Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction (2015) (696)
- A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). (1997) (650)
- Rehospitalization for heart failure: problems and perspectives. (2013) (608)
- Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial (2006) (601)
- Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine (2010) (596)
- Acute heart failure syndromes (2009) (578)
- Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. (2007) (547)
- Association between performance measures and clinical outcomes for patients hospitalized with heart failure. (2007) (535)
- Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). (2008) (531)
- Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. (1986) (514)
- Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. (2003) (495)
- Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). (1999) (489)
- Heart failure with preserved ejection fraction. (2006) (484)
- Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study (2005) (469)
- Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. (2008) (467)
- Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial (2003) (417)
- Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. (2006) (413)
- Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial (2011) (412)
- Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). (2008) (405)
- Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. (2004) (400)
- Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. (2010) (397)
- Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. (2005) (393)
- Consensus recommendations for the management of chronic heart failure: Introduction (1999) (391)
- Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. (2013) (388)
- Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) (2010) (381)
- Endothelial dysfunction, arterial stiffness, and heart failure. (2012) (381)
- Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. (2006) (376)
- Mitochondrial function as a therapeutic target in heart failure (2016) (371)
- Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. (2006) (362)
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial (2013) (362)
- Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial (2004) (345)
- Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. (2004) (341)
- Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. (1999) (340)
- Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing &bgr;-Blocker Therapy (2003) (339)
- Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. (2013) (338)
- Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. (2007) (336)
- HFSA 2006 comprehensive heart failure practice guideline (2006) (329)
- Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. (2004) (329)
- Risk stratification after hospitalization for decompensated heart failure. (2004) (325)
- New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. (2014) (318)
- A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. (1991) (317)
- Developing therapies for heart failure with preserved ejection fraction: current state and future directions. (2014) (317)
- Navigating the Crossroads of Coronary Artery Disease and Heart Failure (2006) (312)
- Fluid overload in acute heart failure — Re‐distribution and other mechanisms beyond fluid accumulation (2008) (295)
- Pathophysiologic targets in the early phase of acute heart failure syndromes. (2005) (286)
- Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. (2015) (285)
- Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) (2008) (280)
- Mitochondria as a therapeutic target in heart failure. (2013) (279)
- Low-dose dobutamine in patients with acute myocardial infarction identifies viable but not contractile myocardium and predicts the magnitude of improvement in wall motion abnormalities in response to coronary revascularization. (1991) (275)
- Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). (2007) (267)
- Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. (2012) (267)
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. (2015) (264)
- Gender differences in survival in advanced heart failure. Insights from the FIRST study. (1999) (261)
- Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. (2004) (257)
- Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study (2017) (251)
- Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. (2010) (250)
- Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. (2008) (245)
- A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease (2016) (240)
- Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease (2018) (238)
- Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. (2003) (238)
- The prevalence and clinical significance of residual myocardial ischemia 2 weeks after uncomplicated non-Q wave infarction: a prospective natural history study. (1986) (235)
- The role of the kidney in heart failure. (2012) (232)
- Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. (2010) (231)
- Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. (2007) (230)
- Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. (2005) (227)
- Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. (2012) (224)
- Vasopressin antagonism in heart failure. (2005) (222)
- Ultrasound lung comets for the differential diagnosis of acute cardiogenic dyspnoea: A comparison with natriuretic peptides ☆ (2008) (222)
- Iron status in patients with chronic heart failure. (2013) (216)
- Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. (2005) (216)
- Vasopressin: a new target for the treatment of heart failure. (2003) (214)
- Cancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging (2016) (212)
- Cardiovascular risk assessment of the liver transplant candidate. (2011) (211)
- Digoxin in the management of cardiovascular disorders. (2004) (209)
- The vulnerable phase after hospitalization for heart failure (2015) (200)
- Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. (1985) (200)
- The problem of decompensated heart failure: nomenclature, classification, and risk stratification. (2003) (199)
- Heart Failure Care in the Outpatient Cardiology Practice Setting: Findings From IMPROVE HF (2008) (198)
- Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. (2011) (195)
- Digoxin. A neurohormonal modulator in heart failure? (1991) (191)
- The burden of acute heart failure on U.S. emergency departments. (2014) (190)
- Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. (2013) (189)
- Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). (2005) (187)
- Contemporary Use of Digoxin in the Management of Cardiovascular Disorders (2006) (187)
- Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). (2007) (186)
- Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document (2013) (183)
- Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. (2006) (182)
- Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. (2008) (182)
- Evidence-based use of levosimendan in different clinical settings. (2006) (179)
- Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. (2008) (178)
- Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. (2008) (178)
- Mode of Death in Heart Failure With Preserved Ejection Fraction. (2017) (178)
- Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. (1997) (177)
- The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. (2010) (176)
- Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage (2015) (175)
- Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. (1992) (174)
- Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). (2008) (173)
- Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. (2001) (170)
- Prevalence and severity of mitral regurgitation in chronic systolic heart failure. (2003) (170)
- A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. (2007) (168)
- Heart failure with preserved ejection fraction: treat now by treating comorbidities. (2008) (168)
- Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. (2008) (165)
- Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. (2012) (163)
- Association between diabetes mellitus and post‐discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial (2013) (162)
- The diabetes epidemic: a national and global crisis. (2004) (161)
- Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial (2012) (160)
- Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. (2007) (156)
- Clinical benefits of low serum digoxin concentrations in heart failure. (2002) (155)
- Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST elevation myocardial infarction (2005) (155)
- Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial (2007) (154)
- Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. (2008) (153)
- Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. (2008) (146)
- Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). (2003) (145)
- Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. (2006) (144)
- Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome (2017) (144)
- A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. (2008) (143)
- ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL (2004) (142)
- Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. (2009) (142)
- Heart failure associated with preserved systolic function: a common and costly clinical entity. (1998) (141)
- Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward (2010) (141)
- Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. (1989) (139)
- Relative lymphocyte count: a prognostic indicator of mortality in elderly patients with congestive heart failure. (2001) (138)
- Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. (2013) (138)
- Targeting myocardial substrate metabolism in heart failure: potential for new therapies (2012) (137)
- Micronutrient deficiencies an unmet need in heart failure. (2009) (132)
- Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. (2013) (132)
- Identifying Patients Hospitalized With Heart Failure at Risk for Unfavorable Future Quality of Life (2011) (129)
- Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. (2003) (129)
- Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. (2012) (128)
- Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. (2013) (128)
- Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. (2006) (127)
- Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. (2011) (127)
- Reassessing treatment of acute heart failure syndromes: the ADHERE Registry (2005) (126)
- Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES) (2014) (125)
- Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. (1996) (125)
- Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis (2013) (125)
- Haemoconcentration, renal function, and post‐discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial (2013) (124)
- Radiographic pulmonary congestion in end-stage congestive heart failure. (1989) (121)
- New insights into diastolic heart failure: role of diabetes mellitus. (2004) (120)
- Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. (2007) (118)
- &bgr;-Blockers in Chronic Heart Failure (2003) (118)
- The current and future management of acute heart failure syndromes. (2010) (118)
- Soluble guanylate cyclase: a potential therapeutic target for heart failure (2013) (118)
- The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction (2013) (118)
- Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORI (2009) (117)
- Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. (1987) (116)
- Psychological Factors Related to Prehospital Delay During Acute Myocardial Infarction (1991) (116)
- Decongestion in acute heart failure (2014) (115)
- Thirty-day readmissions: the clock is ticking. (2013) (114)
- Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. (1995) (113)
- Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. (1995) (113)
- Predictive Value of Dobutamine Stress Echocardiography for Coronary Artery Disease Detection in Liver Transplant Candidates (2008) (112)
- Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm. (1983) (111)
- Cancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions (2016) (111)
- Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). (2009) (111)
- Therapeutic targets in heart failure: refocusing on the myocardial interstitium. (2014) (111)
- Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). (2007) (111)
- n-3 Polyunsaturated Fatty Acids in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion: A Prospective, Randomized Study (2011) (110)
- A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial (2012) (109)
- Dietary Sodium Intake in Heart Failure (2012) (109)
- Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. (2013) (108)
- Depression and clinical outcomes in heart failure: an OPTIMIZE-HF analysis. (2009) (107)
- The past, present and future of renin-angiotensin aldosterone system inhibition. (2013) (106)
- Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. (2009) (106)
- Left Atrium in Heart Failure With Preserved Ejection Fraction: Structure, Function, and Significance (2014) (105)
- Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes (2012) (104)
- Predictive value of stress myocardial perfusion imaging in liver transplant candidates. (2002) (103)
- Review of current and investigational pharmacologic agents for acute heart failure syndromes. (2007) (102)
- The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. (2009) (101)
- Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. (2010) (99)
- Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE‐HF (2012) (99)
- The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. (1990) (98)
- Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. (2008) (96)
- The pathophysiology of advanced heart failure. (1999) (95)
- Why, when, and how to assess pulmonary congestion in heart failure: pathophysiological, clinical, and methodological implications (2009) (93)
- The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. (2014) (92)
- Hyperkalemia in Heart Failure. (2016) (90)
- Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond (2009) (88)
- Critical elements of clinical follow‐up after hospital discharge for heart failure: insights from the EVEREST trial (2010) (88)
- Incremental Reduction in Risk of Death Associated With Use of Guideline-Recommended Therapies in Patients With Heart Failure: A Nested Case-Control Analysis of IMPROVE HF (2012) (88)
- Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. (2010) (88)
- Vasopressin V 2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure Results From a Double-Blind , Randomized Trial (2003) (88)
- Pulmonary edema after pericardiocentesis for cardiac tamponade. (1983) (87)
- Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department. (2008) (87)
- Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. (2013) (86)
- Associations Between Outpatient Heart Failure Process-of-Care Measures and Mortality (2011) (86)
- Effect of oral digoxin in high‐risk heart failure patients: a pre‐specified subgroup analysis of the DIG trial (2013) (85)
- Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. (2003) (85)
- Acute non-Q wave myocardial infarction associated with early ST segment elevation: evidence for spontaneous coronary reperfusion and implications for thrombolytic trials. (1987) (85)
- Heart failure: evaluation of cardiopulmonary transit times with time-resolved MR angiography. (2003) (84)
- Decline in the rate of hospital mortality from acute myocardial infarction: impact of changing management strategies. (1996) (84)
- Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. (2016) (83)
- Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. (2009) (83)
- National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. (2010) (82)
- Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). (2008) (82)
- Rationale and design of the multicentre, randomized, double‐blind, placebo‐controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) (2011) (82)
- HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America. (2000) (81)
- Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure (2007) (79)
- Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights from the EVEREST Trial (2012) (78)
- Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy (2007) (78)
- Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspective, Mechanisms, and Future Directions (2011) (77)
- Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study‐Heart Failure (ARTS‐HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease (2015) (77)
- The disconnect between phase II and phase III trials of drugs for heart failure (2013) (77)
- The Valsalva maneuver: a bedside "biomarker" for heart failure. (2006) (76)
- Comparison of Medical Therapy Dosing in Outpatients Cared for in Cardiology Practices With Heart Failure and Reduced Ejection Fraction With and Without Device Therapy: Report From IMPROVE HF (2010) (76)
- Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study (2017) (75)
- The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. (2013) (75)
- Digitalis Investigation Group (DIG) trial: a stimulus for further research. (1997) (73)
- Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZE‐HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) * (2008) (71)
- The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). (2005) (71)
- Cachexia: common, deadly, with an urgent need for precise definition and new therapies. (2008) (71)
- Hypercatabolic syndrome: molecular basis and effects of nutritional supplements with amino acids. (2008) (71)
- Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate‐lowering properties (2014) (71)
- Concomitant diabetes mellitus and heart failure. (2015) (71)
- Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. (2007) (71)
- Rationale and design of ARTS: a randomized, double‐blind study of BAY 94‐8862 in patients with chronic heart failure and mild or moderate chronic kidney disease (2012) (70)
- Day of Admission and Clinical Outcomes for Patients Hospitalized for Heart Failure: Findings From the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) (2008) (70)
- Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. (2012) (69)
- Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. (2003) (69)
- Population Risk Prediction Models for Incident Heart Failure: A Systematic Review (2015) (69)
- Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. (2007) (69)
- Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review (2016) (69)
- Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. (2001) (69)
- Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the ATTEND registry). (2013) (68)
- Safety and Efficacy of Epoprostenol in Patients with Severe Congestive Heart Failure (1995) (68)
- Hyponatremia in patients with heart failure. (2005) (68)
- Effects of tolvaptan on dyspnoea relief from the EVEREST trials. (2009) (68)
- Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. (2013) (67)
- The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. (2012) (67)
- The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy (2009) (66)
- Reconsidering the role for digoxin in the management of acute heart failure syndromes. (2009) (66)
- Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Insights From the EVEREST Trial (2013) (65)
- Postdischarge assessment after a heart failure hospitalization: the next step forward. (2010) (64)
- Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. (2013) (64)
- International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes (2010) (64)
- The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. (2011) (63)
- &bgr;-Blockers in the Post-Myocardial Infarction Patient (2002) (63)
- Malnutrition, muscle wasting and cachexia in chronic heart failure: the nutritional approach. (2003) (63)
- Coronary artery disease in patients with heart failure and preserved systolic function. (2002) (62)
- Pharmacology of new agents for acute heart failure syndromes. (2005) (62)
- Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. (2013) (61)
- Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure (2013) (61)
- Frequency and significance of acute heart failure following liver transplantation. (2008) (61)
- Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. (2014) (61)
- Global variation in clinical profile, management, and post‐discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial (2015) (59)
- Developing New Treatments for Heart Failure: Focus on the Heart (2016) (59)
- Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. (2011) (58)
- Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). (2014) (57)
- Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. (2004) (57)
- A proposed model for initial assessment and management of acute heart failure syndromes. (2011) (57)
- A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. (2008) (57)
- In‐hospital worsening heart failure (2015) (57)
- The impact of arrhythmias in acute heart failure. (2004) (56)
- Serum aldosterone is associated with mortality and re‐hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial (2013) (56)
- Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions (2014) (56)
- Exercise-induced coronary spasm with S-T segment depression and normal coronary arteriography. (1981) (56)
- Standards of laboratory practice: cardiac drug monitoring (1998) (56)
- Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. (2013) (55)
- Digoxin--new perspective on an old drug. (2002) (55)
- The immunological axis in heart failure: importance of the leukocyte differential (2013) (55)
- Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. (1995) (54)
- Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. (2009) (54)
- Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure (2015) (54)
- Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF. (2009) (53)
- Diastolic heart failure: standard Doppler approach and beyond. (1998) (53)
- The pathophysiology of advanced heart failure. (1998) (52)
- Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. (2015) (52)
- Acute heart failure syndromes and coronary perfusion. (2008) (52)
- Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges (2018) (52)
- Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. (2009) (51)
- Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis (2017) (51)
- Length of hospital stay and 30‐day readmission following heart failure hospitalization: insights from the EVEREST trial (2015) (51)
- Resting Heart Rate and Risk of Incident Heart Failure: Three Prospective Cohort Studies and a Systematic Meta‐Analysis (2015) (51)
- Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. (2008) (51)
- "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. (2015) (51)
- Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure (2002) (51)
- Angiotensin receptor blockers and outcomes in real‐world older patients with heart failure and preserved ejection fraction: a propensity‐matched inception cohort clinical effectiveness study (2012) (50)
- Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). (2013) (49)
- Overview of emerging pharmacologic agents for acute heart failure syndromes (2008) (49)
- Review of randomized trials of digoxin therapy in patients with chronic heart failure. (1992) (48)
- Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. (1997) (48)
- Left Ventricular Dysfunction With Pulmonary Hypertension: Part 1 Epidemiology, Pathophysiology, and Definitions (2013) (48)
- A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function. (2007) (47)
- Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. (2006) (47)
- Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review. (2004) (47)
- International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT‐HF): rationale for and design of a global registry (2015) (47)
- Molecular and Cellular Basis of Viable Dysfunctional Myocardium (2014) (47)
- Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. (2011) (47)
- Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives. (2013) (47)
- Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic CardiomyopathyNovelty and Significance (2017) (47)
- Metoprolol CR/XL in patients with heart failure: A pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. (1999) (46)
- Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. (2000) (46)
- Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. (2013) (46)
- Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30% (2006) (46)
- Hemoconcentration-guided diuresis in heart failure. (2014) (46)
- Global Perspectives in Hospitalized Heart Failure: Regional and Ethnic Variation in Patient Characteristics, Management, and Outcomes (2014) (46)
- Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). (2010) (45)
- Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na–K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? (2009) (45)
- Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure. (2002) (45)
- Current medical therapy for advanced heart failure. (1998) (45)
- Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics (2017) (45)
- Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction (2016) (45)
- Management of comorbid diabetes mellitus and worsening heart failure. (2014) (44)
- Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient—part 1 (2009) (44)
- Day of Admission and Clinical Outcomes for Patients Hospitalized for Heart FailureCLINICAL PERSPECTIVE (2008) (44)
- More than bricks and mortar: comments on protein and amino acid metabolism in the heart. (2008) (44)
- Risk identification at the time of admission to coronary care unit in patients with suspected myocardial infarction. (1988) (44)
- Current medical therapy for advanced heart failure. (2000) (44)
- Improvement in Hypertension in Patients With Diabetes Mellitus After Kidney/Pancreas Transplantation (2001) (44)
- Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. (2010) (44)
- Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. (2003) (44)
- Strategies and opportunities for drug development in heart failure. (2013) (43)
- Role of guanylate cyclase modulators in decompensated heart failure (2009) (43)
- Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization. (2010) (43)
- Coronary multidetector computed tomographic angiography to evaluate coronary artery disease in liver transplant candidates: methods, feasibility and initial experience (2011) (43)
- Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes. (2014) (42)
- Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. (1998) (42)
- Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). (2009) (42)
- A propensity matched study of the association of education and outcomes in chronic heart failure. (2008) (42)
- Epidemiology and outcome of the cardio-renal syndrome (2011) (41)
- Echocardiographic evaluation of left ventricular structure and function: new modalities and potential applications in clinical trials. (2012) (41)
- Congestion as a therapeutic target in acute heart failure syndromes. (2010) (41)
- B-type natriuretic peptide: from bench to bedside. (2003) (41)
- Pharmacotherapy for systolic dysfunction: a review of randomized clinical trials. (1997) (41)
- EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (2008) (41)
- Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. (2011) (40)
- Myocardial Damage Detected by Late Gadolinium Enhancement Cardiovascular Magnetic Resonance Is Associated With Subsequent Hospitalization for Heart Failure (2013) (40)
- Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round‐table think tank on acute heart failure, 12 May 2009 (2011) (40)
- Is there a role for thiamine supplementation in the management of heart failure? (1996) (40)
- Mechanisms and management of heart failure due to diastolic dysfunction. (1996) (40)
- Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. (2011) (39)
- The impact of coronary artery disease on outcomes after liver transplantation (2016) (39)
- Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). (2015) (39)
- Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. (2013) (39)
- Hyponatremia in heart failure (2008) (38)
- Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. (2013) (38)
- Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction (2016) (38)
- Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure (2010) (38)
- Relationship of Clinical Signs and Chest-X Ray Congestion to the Efficacy of Digoxin in Patients with Chronic Heart Failure: A Retrospective Analysis of the Digoxin Investigation Group Trial (2006) (38)
- Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis (2017) (38)
- Patients with mild heart failure worsen during withdrawal from digoxin therapy. (1997) (38)
- Simultaneous pancreas-kidney transplantation in the mycophenolate mofetil/tacrolimus era: evolution from induction therapy with bladder drainage to noninduction therapy with enteric drainage. (2000) (38)
- Clinical Effectiveness of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Men and Women With Heart Failure: Findings From IMPROVE HF (2014) (38)
- Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. (2014) (38)
- Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. (2001) (38)
- Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. (1990) (37)
- Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. (2011) (37)
- Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with chronic obstructive pulmonary disease. (1998) (37)
- Platypnea and interatrial right-to-left shunting after lobectomy. (1983) (36)
- Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure (2017) (36)
- The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy. (2012) (36)
- Predictors of delivery of hospital-based heart failure patient education: a report from OPTIMIZE-HF. (2007) (36)
- Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure (2016) (36)
- Is heart failure survival improving? Evidence from 2323 elderly patients hospitalized between 1989-2000. (2003) (36)
- Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. (2004) (35)
- Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction: Findings From the EVEREST Trial (2014) (35)
- Tolvaptan for the treatment of heart failure: a review of the literature (2011) (35)
- Electronic health records and quality of care for heart failure. (2010) (35)
- Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. (2012) (35)
- Optimal heart rate control for patients with chronic atrial fibrillation: are pharmacologic choices truly changing? (1992) (34)
- Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment (2012) (34)
- Learning from recent trials and shaping the future of acute heart failure trials. (2013) (34)
- Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification: insights from the IMPROVE HF registry. (2014) (33)
- Reappraisal of beta-blocker therapy in the acute and chronic post-myocardial infarction period. (2004) (33)
- Hospitalizations for heart failure in the United States--a sign of hope. (2011) (33)
- Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. (2013) (33)
- Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction † (2013) (33)
- Lower thrombolytic use for African Americans with myocardial infarction: an influence of clinical presentation? (1999) (33)
- The Role of Echocardiography in the Diagnosis and Management of Heart Failure (2003) (33)
- Neurohormonal inhibition in heart failure: insights from recent clinical trials. (2005) (32)
- Natriuretic peptide-guided management in heart failure (2016) (32)
- Serial evaluation of left ventricular function in congestive heart failure by measurement of peak aortic blood acceleration. (1988) (32)
- Prevention and management of chronic heart failure in patients at risk. (2003) (32)
- The challenge of acute decompensated heart failure (2006) (32)
- Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department. (2003) (32)
- Effects of Elamipretide on Left Ventricular Function in Patients with Heart Failure with Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. (2020) (32)
- Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. (2011) (32)
- Blockers in Chronic Heart Failure (2003) (31)
- Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. (2015) (31)
- Congestion is an important diagnostic and therapeutic target in heart failure. (2006) (31)
- Heart failure: Early follow-up after hospitalization for heart failure (2010) (31)
- Antithrombotic therapy in atrial fibrillation: a review of randomized trials with special reference to the Stroke Prevention in Atrial Fibrillation II (SPAF II) Trial. (1996) (31)
- Water and Sodium in Heart Failure: A Spotlight on Congestion (2014) (31)
- Pharmacological treatment of chronic heart failure (2006) (31)
- Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. (2007) (30)
- Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial). (2004) (30)
- Tricuspid valve replacement for cardiogenic shock after acute right ventricular infarction. (1980) (30)
- Hemodynamic Evaluation Before Liver Transplantation: Insights Into the Portal Hypertensive Syndrome (2007) (30)
- Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. (2014) (30)
- Pre‐discharge and early post‐discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial (2018) (29)
- Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. (2011) (29)
- Anticoagulation in heart failure: current status and future direction (2013) (29)
- Lessons learned in acute heart failure (2018) (29)
- Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between likert and visual analog scales. (2014) (29)
- Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial (2015) (28)
- Relation between plasma norepinephrine and response to medical therapy in men with congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. (1989) (28)
- HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction--pharmacological approaches. (2000) (28)
- Acute heart failure: the role of focused emergency cardiopulmonary ultrasound in identification and early management (2015) (28)
- Partial Adenosine A1 Agonist in Heart Failure. (2016) (28)
- Cardiac event rate after non-Q-wave acute myocardial infarction and the significance of its anterior location. (1989) (28)
- Trends in characteristics of cardiovascular clinical trials 2001-2012. (2015) (27)
- Equitable improvement for women and men in the use of guideline-recommended therapies for heart failure: findings from IMPROVE HF. (2010) (27)
- A Neurohormonal Modulator in Heart Failure? (2005) (27)
- The rationale for an acute heart failure syndromes clinical trials network. (2009) (27)
- Technical and immunologic progress in simultaneous pancreas-kidney transplantation. (2002) (27)
- Introduction to acute heart failure syndromes. (2005) (27)
- Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations (2013) (27)
- Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period (2011) (27)
- Left Ventricular Dysfunction With Pulmonary Hypertension: Part 2: Prognosis, Noninvasive Evaluation, Treatment, and Future Research (2013) (26)
- The bumpy road to drug development for acute heart failure (2016) (26)
- Coronary artery disease and prevention of heart failure. (2004) (25)
- Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not? (2013) (25)
- Overview of current noninodilator therapies for acute heart failure syndromes. (2005) (25)
- Amino acids and derivatives, a new treatment of chronic heart failure? (2014) (25)
- A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. (1999) (25)
- Acute and chronic hemodynamic effects of nicardipine hydrochloride in patients with heart failure. (1987) (25)
- Transthoracic and transesophageal echocardiography in the hemodynamic assessment of patients with congestive heart failure. (2000) (25)
- Agents with vasodilator properties in acute heart failure: how to design successful trials (2015) (25)
- Effects of Oral Amino Acid Supplements on Functional Capacity in Patients with Chronic Heart Failure (2014) (25)
- Trends in Heart Failure Clinical Trials From 2001-2012. (2016) (25)
- Modern management of acute heart failure syndromes (2005) (25)
- Digoxin for Chronic Heart Failure: A Review of the Randomized Controlled Trials With Special Attention to the PROVED and RADIANCE Trials (1994) (24)
- Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality? (2009) (24)
- Prognostic markers in heart failure—congestion, neurohormones, and the cardiorenal syndrome (2007) (24)
- The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry (2013) (24)
- Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. (2015) (24)
- Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1‐receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction (2018) (24)
- Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). (2010) (24)
- Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. (2012) (24)
- Carvedilol: beta-blockade and beyond. (2004) (23)
- Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure. (1995) (23)
- Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. (2017) (23)
- Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). (2001) (23)
- Life-threatening hyperkalemia in severe heart failure. (1989) (23)
- Digoxin for the treatment of chronic and acute heart failure syndromes (2009) (23)
- Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: a propensity-matched study of the EPHESUS trial. (2010) (23)
- The challenge of acute heart failure syndromes. (2005) (23)
- Rationale and Design of the Hemodynamic, Echocardiographic and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure (HORIZON-HF) Trial (2008) (23)
- Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry (2015) (23)
- Closing statement. (2004) (22)
- Lack of Association Between Electronic Health Record Systems and Improvement in Use of Evidence‐Based Heart Failure Therapies in Outpatient Cardiology Practices (2012) (22)
- Long term clinical and neurohormonal effects of nicardipine in patients with severe heart failure on maintenance therapy with angiotensin converting enzyme inhibitors (1991) (22)
- Short- and long-term treatment of stable effort angina with nicardipine, a new calcium channel blocker: a double-blind, placebo-controlled, randomised, repeated cross-over study. (1985) (22)
- Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. (1995) (22)
- Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). (2010) (22)
- Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. (2016) (22)
- Acute Hemodynamic Effects of Tolvaptan , a Vasopressin V 2 Receptor Blocker , in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International , Multicenter , Randomized , Placebo-Controlled Trial (2008) (22)
- Beta‐blocker therapy in advanced heart failure: clinical characteristics and long‐term outcomes (1999) (21)
- Influence of atrial fibrillation on post‐discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial (2017) (21)
- Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry (2016) (21)
- Beyond dyspnoea as an endpoint in acute heart failure trials. (2011) (21)
- Diuretic therapy in heart failure: current controversies and new approaches for fluid removal (2010) (21)
- Surrogate end points in heart failure trials. (2003) (21)
- OPTIME in CHF trial: rethinking the use of inotropes in the management of worsening chronic heart failure resulting in hospitalization (2003) (21)
- Diagnosis and Management of Acute Heart Failure Syndromes (2012) (21)
- Incident heart failure in relation to vascular disease: Insights from the Health, Aging, and Body Composition Study (2014) (20)
- Vasopressin and vasopressin antagonists in heart failure and hyponatremia (2008) (20)
- Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology-findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training study. (2011) (20)
- Patterns of angiotensin‐converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure (1998) (20)
- Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. (2011) (20)
- Pharmacologic therapies after myocardial infarction. (1996) (20)
- Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial (2016) (20)
- Estimating severity of chronic heart failure: a clinical challenge for the 1990s. (1992) (20)
- Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: If You Are Confused, Remember: “It Is a Matter of the Heart” (2012) (20)
- Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial (2013) (20)
- Chapter 49 Acute heart failure: epidemiology, classification, and pathophysiology (2010) (20)
- Monotherapy of stable angina with nicardipine hydrochloride: double-blind, placebo-controlled, randomized study. (1989) (20)
- Pharmacist interventions to improve the management of coronary artery disease. (2004) (19)
- The underuse of digoxin in heart failure, and approaches to appropriate use (2007) (19)
- Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure. (1998) (19)
- Percutaneous Mitral Valve Repair With the MitraClip System for Severe Mitral Regurgitation in Patients With Surgical Mitral Valve Repair Failure (2014) (19)
- Regional Validation and Recalibration of Clinical Predictive Models for Patients With Acute Heart Failure (2017) (19)
- Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart (2015) (19)
- Management of post-myocardial infarction patients with left ventricular systolic dysfunction. (2007) (19)
- Effects of propanolol in patients entered in the Beta-Blocker Heart Attack Trial with their first myocardial infarction and persistent electrocardiographic ST-segment depression. (1998) (19)
- Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). (2016) (18)
- Differentiation of Arginine Vasopressin Antagonistic Effects by Selective V2 versus Dual V2/V1a Receptor Blockade in a Preclinical Heart Failure Model (2011) (18)
- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). (2002) (18)
- The current role of digoxin in the treatment of heart failure. (1993) (18)
- Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection Fraction (2010) (18)
- Geographic variation in heart failure trials: time for scepticism? (2014) (18)
- Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature (2013) (18)
- The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. (2009) (18)
- Acute and long-term hemodynamic effects of oral pirbuterol in patients with chronic severe congestive heart failure: randomized double-blind trial. (1983) (18)
- Timing and Duration of Interventions in Clinical Trials for Patients With Hospitalized Heart Failure (2013) (18)
- Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. (2020) (18)
- Mobile health applications in cardiovascular research. (2018) (17)
- Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade. (2006) (17)
- Redefining the role of biomarkers in heart failure trials: expert consensus document (2017) (17)
- Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial (2013) (17)
- Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender (2016) (17)
- Acute Heart Failure With Low Cardiac Output: Can We Develop a Short-term Inotropic Agent That Does Not Increase Adverse Events? (2010) (17)
- AHA Scientific Statement Acute Heart Failure Syndromes : Emergency Department Presentation , Treatment , and Disposition : Current Approaches and Future Aims (2010) (17)
- Update on digoxin and other oral positive inotropic agents for chronic heart failure. (1997) (16)
- Abnormalities of skeletal muscle metabolism during nerve stimulation determined by 31P nuclear magnetic resonance spectroscopy in severe congestive heart failure. (1995) (16)
- Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial (2017) (16)
- Drug therapy to reduce early readmission risk in heart failure: ready for prime time? (2013) (16)
- Site selection for heart failure clinical trials in the USA (2015) (16)
- Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial (2016) (16)
- Adherence to Aldosterone-Blocking Agents in Patients with Heart Failure (2010) (16)
- Prognostic significance of electrocardiographic persistent ST depression in patients with their first myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. (1993) (16)
- Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. (2005) (16)
- Same protocol, different continents, different patients: should we continue to conduct global heart failure trials? (2015) (16)
- Normalization of Ejection Fraction and Resolution of Symptoms in Chronic Severe Heart Failure is Possible With Modern Medical Therapy: Clinical Observations in 11 Patients (2008) (16)
- Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with He (2010) (16)
- Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients (2002) (16)
- Beta Blocker Therapy After Acute Myocardial Infarction in Patients with Heart Failure and Systolic Dysfunction (2004) (16)
- Role of carvedilol in atrial fibrillation: insights from clinical trials. (2004) (16)
- Managed care interventions for improving outcomes in acute heart failure syndromes. (2008) (15)
- Nutritional assessment and support of the patient with acute heart failure (2010) (15)
- Practical aspects of using beta-adrenergic blockade in systolic heart failure. (2001) (15)
- Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). (2012) (15)
- Medical management of heart failure secondary to coronary artery disease. (1998) (15)
- Digoxin use in atrial fibrillation: a critical reappraisal (2015) (15)
- Rationale, design, and results from RENO-DEFEND 1: a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. (2011) (15)
- Prevalence, Mechanisms, and Clinical Implications (2010) (15)
- Factors Associated with Improvement in Guideline‐Based Use of ICDs in Eligible Heart Failure Patients (2012) (15)
- Natural history of the first non-Q wave myocardial infarction in the placebo arm of the Beta-Blocker Heart Attack Trial. (1991) (14)
- Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. (2016) (14)
- In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial. (2016) (14)
- Moving away from symptoms‐based heart failure treatment: misperceptions and real risks for patients with heart failure (2016) (14)
- Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia. (2006) (14)
- Standards of laboratory practice: cardiac drug monitoring. National Academy of Clinical Biochemistry. (1998) (14)
- The clinical effects of vasopressin receptor antagonists in heart failure. (2006) (14)
- Hemodynamic response of a canine model of chronic heart failure to intravenous dobutamine, nitroprusside, enalaprilat, and digoxin (1993) (14)
- Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. (1998) (14)
- Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure. (1992) (14)
- A Randomized, Double-Blind Comparison of Lercanidipine 10 and 20 mg in Patients with Stable Effort Angina: Clinical Evaluation of Cardiac Function by Ambulatory Ventricular Scintigraphic Monitoring (2004) (14)
- Rate and extent of recovery of left ventricular function in patients following acute myocardial infarction. (1987) (13)
- Clinical and Neurohormonal Effects of Nicardipine Hydrochloride in Patients With Severe Chronic Heart Failure Receiving Angiotensin‐Converting Enzyme Inhibitor Therapy (1998) (13)
- Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations (2017) (13)
- Design and Rationale of the URGENT Dyspnea Study: An International, Multicenter, Prospective Study (2008) (13)
- Digitoxin prolongs survival of female rats with heart failure due to large myocardial infarction. (2009) (13)
- Think Small and Examine the Constituents of Left Ventricular Hypertrophy and Heart Failure: Cardiomyocytes Versus Fibroblasts, Collagen, and Capillaries in the Interstitium (2015) (13)
- Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients with Symptomatic Heart Failure and Systolic Dysfunction: The ECLIPSE International, Multicenter, Randomized, Placebo-controlled Trial (2007) (13)
- Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy (2012) (13)
- Challenge of rehospitalizations for heart failure: potential of natriuretic doses of mineralocorticoid receptor antagonists. (2011) (12)
- Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III (2010) (12)
- The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. (2002) (12)
- Is there a clinically meaningful difference in patient reported dyspnea in acute heart failure? An analysis from URGENT Dyspnea (2017) (12)
- Utility of positron emission tomography for drug development for heart failure. (2016) (12)
- Vasopressin V1 receptor‐mediated aldosterone production as a result of selective V2 receptor antagonism: a potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial (2011) (12)
- Effect of &bgr;-Blockade on the Premature Ventricular Beats/Heart Rate Relation and Heart Rate Variability in Patients with Coronary Heart Disease and Severe Ventricular Arrhythmias (2000) (11)
- Fiolan International Randomized Survival Trial (FIRST): Final results (1996) (11)
- Serum chloride in heart failure: a salty prognosis (2016) (11)
- Left ventricular function after successful percutaneous transluminal coronary angioplasty for postinfarction angina pectoris. (1988) (11)
- Erratum to: Epidemiology and outcome of the cardio-renal syndrome (2011) (11)
- Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. (2003) (11)
- Role of neurohormonal modulators in heart failure with relatively preserved systolic function. (2005) (11)
- Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina. (1997) (11)
- Design of a multicenter, double-blind study to assess the effects of prophylactic diltiazem on early reinfarction after non-Q-wave acute myocardial infarction: diltiazem reinfarction study. (1986) (11)
- Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure (2006) (11)
- Real‐world dosing of evidence‐based medications for heart failure: embracing guideline recommendations and clinical judgement (2017) (11)
- Non-Invasive Cardiac Evaluation in Heart Failure Patients Using Magnetic Resonance Imaging: A Feasibility Study (2005) (11)
- Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial (2019) (11)
- Acute Dyspnea and Decompensated Heart Failure. (2018) (10)
- Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists (2015) (10)
- Assessment and management of coronary artery disease in kidney and pancreas transplant candidates. (2019) (10)
- 788-2 Six Minute Walk Test Gives Prognostic Information in Severe Hear Failure (1995) (10)
- Prognostic value of hyponatremia in hospitalized patients with worsening heart failure - insights from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME - CHF) (2003) (10)
- USE OF N-3 POLYUNSATURATED FATTY ACIDS TO MAINTAIN SINUS RHYTHM AFTER CONVERSION FROM PERSISTENT ATRIAL FIBRILLATION. A PROSPECTIVE RANDOMIZED STUDY (2010) (10)
- Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? (2017) (10)
- Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction. (2013) (10)
- Critical reappraisal of pulmonary artery catheterization and invasive hemodynamic assessment in acute heart failure (2013) (9)
- Novel Endpoints for Heart Failure Clinical Trials (2017) (9)
- American Journal of Medicine: Introduction and overview (2001) (9)
- Phase II trials in heart failure: the role of cardiovascular imaging. (2011) (9)
- Epidemiology of atrial fibrillation in patients hospitalized in a large hospital. (1993) (9)
- Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). (2012) (9)
- RANDOMIZED INTRAVENOUS TEZOSENTAN STUDY-4 INVESTIGATORS TEZOSENTAN IN PATIENTS WITH ACUTE HEART FAILURE AND ACUTE CORONARY SYNDROMES (2003) (9)
- Therapy for acute heart failure syndromes (2009) (9)
- The potential role of cardiac resynchronization therapy in acute heart failure syndromes (2011) (9)
- The role of the emergency department in acute heart failure clinical trials--enriching patient identification and enrollment. (2013) (9)
- Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). (2003) (9)
- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). (2002) (9)
- Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). (2013) (9)
- The pathophysiology of advanced heart failure (Reprinted from Am Heart J, vol 135, pg S216-S230, 1998) (1999) (9)
- Are the American College of Cardiology/Emergency Cardiac Care (ACC/ECC) guidelines useful in triaging patients to telemetry units? (2006) (9)
- Is there a role for epoprostenol in the management of heart failure? (1995) (9)
- Treatment of acute decompensated heart failure with the soluble guanylate cyclase activator cinaciguat: The COMPOSE program – three randomized, controlled, phase IIb studies (2011) (9)
- Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). (2014) (8)
- Factors Associated with Improvement in Utilization of Cardiac Resynchronization Therapy in Eligible Heart Failure Patients: Findings from IMPROVE HF (2013) (8)
- Treatment of congestion in acute heart failure syndromes: importance, strategies, and challenges. Introduction. (2006) (8)
- A review of phase II acute heart failure syndromes clinical trials. (2011) (8)
- Early pharmacological treatment of acute heart failure syndromes: A systematic review of clinical trials (2007) (8)
- Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. (2003) (8)
- Digoxin Therapy in Chronic Heart Failure (1997) (8)
- Tolvaptan for the treatment of hyponatremia and congestive heart failure. (2006) (8)
- Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone. European Myocardial Infarct Amiodarone Trial. Canadian Amiodarone Myocardial Infarction Trial. (1998) (8)
- Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads (2016) (8)
- Heart failure in 2010: One step forward, two steps back (2011) (8)
- Race and improvements in the use of guideline-recommended therapies for patients with heart failure: findings from IMPROVE HF. (2012) (8)
- Introduction and overview: beta-blocker therapy in the management of chronic heart failure. (2001) (8)
- Pulmonary Oedema-Therapeutic Targets. (2015) (8)
- Acute heart failure syndromes: assessment and reconstructing the heart (2011) (8)
- Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy (2017) (8)
- Congestion in acute heart failure syndromes: importance of early recognition and treatment. (2006) (7)
- Intravenous digoxin for patients with severe heart failure (1987) (7)
- Current medical therapy for advanced heart failure (Reprinted from Am Heart, vol 135, pg S231-S248, 1998) (2000) (7)
- Hospitalization for worsening chronic heart failure. (2004) (7)
- Digoxin for Worsening Chronic Heart Failure: Underutilized and Underrated. (2016) (7)
- Expanded algorithm for managing patients with acute decompensated heart failure (2018) (7)
- patient and practice factors associated with improvement in use of guideline-recommended therapies for outpatients with heart failure (from the IMPROVE HF trial). (2011) (7)
- Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. (2017) (7)
- Standardized reporting criteria for studies evaluating suspected acute heart failure syndromes in the emergency department. (2012) (7)
- Early intravenous beta-blocker combined with thrombolytic therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI-2) Trial. (1993) (7)
- Acute heart failure syndromes: Epidemiology, risk stratification and prognostic factors (2009) (7)
- A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. (2018) (7)
- Body mass index, gender, and clinical outcome among hypertensive and diabetic patients with stage A/B heart failure (2013) (7)
- Mitral regurgitation in chronic heart failure: More questions than answers? (2004) (6)
- Aldosterone blockade in post‐acute myocardial infarction heart failure (2006) (6)
- Clinical trials in acute heart failure: beginning of the end or end of the beginning? (2017) (6)
- Carvedilol: β-Blockade and Beyond (2004) (6)
- Vasopressin antagonists in the management of heart failure (2007) (6)
- A new educational program in heart failure drug development: the Brescia international master program (2018) (6)
- Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure? (2018) (6)
- A Randomized, Double-Blind Comparison of 10 and 20 mg Lercanidipine in Patients With Stable Effort Angina: Effects on Myocardial Ischemia and Heart Rate Variability (2002) (6)
- Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). (2018) (6)
- Targeting digoxin dosing to serum concentration: is the bullseye too small? (2016) (6)
- Role of vasopressin antagonists in the management of acute decompensated heart failure (2005) (6)
- EXTRACELLULAR MATRIX EXPANSION IN NON-INFARCTED MYOCARDIUM IS ASSOCIATED WITH SUBSEQUENT DEATH, HOSPITALIZATION FOR HEART FAILURE, OR BOTH ACROSS THE EJECTION FRACTION SPECTRUM (2014) (6)
- Mechanical circulatory support devices for acute heart failure syndromes: considerations for clinical trial design (2008) (6)
- Aldosterone receptor blockade in patients with left ventricular systolic dysfunction following acute myocardial infarction. (2008) (6)
- Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. (2004) (6)
- The EPHESUS trial: evaluation of eplerenone in the subgroup of patients with baseline left ventricular ejection fraction ≤30% (2003) (5)
- Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of IMPROVE HF (2009) (5)
- 787 Prognostic value and changes in renal function in patients admitted with acute heart failure - results from the EVEREST program (2008) (5)
- Reply: considerations for drug development for heart failure. (2015) (5)
- Expanding the scope of the "polypill" to heart failure. (2013) (5)
- Sunday, 26 August 2012 (2012) (5)
- Calcium channel blockers in the management of myocardial infarction patients. (1991) (5)
- Myocardial fibrosis is associated with subsequent death and hospitalization for heart failure in obese adults (2015) (5)
- Treatment gaps in the pharmacologic management of heart failure. (2002) (5)
- Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization (2016) (5)
- Acute dose-response, double-blind, placebo-controlled pilot study of lercanidipine in patients with angina pectoris (2000) (5)
- 1069-119 Predictors of mortality in patients hospitalized with worsening heart failure: Insights from the ACTIV in CHF trial (2004) (5)
- B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF (2012) (5)
- Natriuretic peptide-guided management in heart failure. (2015) (4)
- Gender differences in survival in patients with advanced heart failure. (1996) (4)
- Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions (2011) (4)
- Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. (2017) (4)
- Reassessing the use of vasodilators in heart failure (2012) (4)
- Subgroup analysis of clinical trials. (1991) (4)
- Oral anticoagulation for secondary prevention after myocardial infarction with special reference to the warfarin re-infarction study. (1992) (4)
- Past, present, and future of acute heart failure clinical trials—a high‐risk population in search of a strategy (2018) (4)
- Lipids, statins, and clinical outcomes in heart failure: rethinking the data (2014) (4)
- Initial Hospital, Patient, and Performance Measure Characteristics of the Organized Program To Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) Program (2004) (4)
- Therapeutic strategies for patients hospitalized with worsening heart failure. (2003) (4)
- Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin. (2004) (4)
- The editor's roundtable: Acute decompensated heart failure. (2007) (4)
- Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. (2003) (4)
- Tezosentan in patients with acuteheart failure and acute coronary syndromes (2003) (4)
- Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes. (2007) (4)
- Seeking new heights in acute heart failure syndromes: lessons from ASCEND and EVEREST. (2013) (4)
- Heart Failure in the Elderly: Implications for Rehabilitation (2000) (4)
- Role of neurohormonal modulators in heart failure with relatively preserved systolic function. (2008) (4)
- Statement From the American Heart Association Treatment, and Disposition: Current Approaches and Future Aims. A Scientific Acute Heart Failure Syndromes: Emergency Department Presentation, (2010) (4)
- Hyponatremia in acute heart failure syndromes: A potential therapeutic target (2007) (4)
- Clinical profiles in acute heart failure: one size fits all or not at all? (2017) (4)
- Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. (2015) (4)
- Assessment and key targets for therapy in the post-myocardial infarction patient with left ventricular dysfunction. (2008) (4)
- The editor's roundtable: pathophysiology and management of hyponatremia and the role of vasopressin antagonists. (2011) (4)
- Calcium-channel blockers in postmyocardial infarction patients with special notation to the Danish verapamil infarction trial II. (1991) (4)
- Management of cardiogenic shock complicating acute myocardial infarction: The Henry Ford Hospital experience and review of the literature. (1991) (3)
- Progress or lack of progress in hospitalized heart failure (2013) (3)
- Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy? (2014) (3)
- Current status of acute intravenous therapy for chronic heart failure exacerbations (1999) (3)
- Intravenous therapy for chronic heart failure exacerbations. (1999) (3)
- Thirty-Day Readmissions (2017) (3)
- Eplerenone reduces risk of cardiovascular death or hospitalisation in heart failure patients with reduced ejection fraction (2011) (3)
- 250 Mode of death and cardiovascular re‐hospitalization in patients admitted with acute heart failure ‐ results from the EVEREST program (2008) (3)
- Monday, 27 August 2012 (2012) (3)
- Revisiting cardiac injury during acute heart failure: further characterization and a possible target for therapy. (2015) (3)
- HEART FAILURE SOCIETY OF AMERICA (HFSA) PRACTICE GUIDELINES (2000) (3)
- Special cases in acute heart failure syndromes: atrial fibrillation and wide complex tachycardia. (2009) (3)
- Pancreas transplantation at Northwestern University. (2000) (3)
- Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations (2015) (3)
- Acute heart failure syndromes: Potential strategies to improve post-discharge outcomes (2008) (3)
- Return of digoxin and recovery of renal function. (2013) (3)
- Neurohumoral effects of digoxin: a target for further investigation. (1996) (3)
- Acute heart failure treatment: traditional and new drugs. (2010) (3)
- The potential application of electrophysiology diagnostics and therapeutics in acute heart failure syndromes (2011) (3)
- Heart failure as a consequence of atherosclerotic coronary artery disease (2003) (3)
- Isolated right heart tamponade following mediastinal irradiation. (1986) (3)
- Arrhythmia suppression in postmyocardial infarction patients with special notation to cardiac arrhythmia suppression trial. (1991) (3)
- 114 Anemia as a predictor of death and rehospitalization in patients with advanced decompensated heart failure: insights from the OPTIME‐CHF study (2003) (3)
- Systolic Blood Pressure and Outcomes in Patients Hospitalized With Acute Heart Failure—Reply (2007) (3)
- The Liver in Cardiovascular Disease (2008) (3)
- Roadmap to inpatient heart failure management. (2015) (3)
- Heart Failure as a Consequence of Ischemic Heart Disease (2020) (3)
- Management of high-risk subsets in unstable angina. (1999) (3)
- Pathophysiology of chronic heart failure. Discussion (2001) (3)
- Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). (2015) (3)
- Reply: BAG3 protein in advanced-stage heart failure. (2014) (3)
- Echocardiographic features of truncal abnormalities. Special emphasis to the evaluation of pulmonary arteries. (1984) (2)
- Chronic heart failure: a manifestation of coronary artery disease (2000) (2)
- Endpoints for diuresis: are we there yet? (2014) (2)
- Nisoldipine and myocardial infarction. (1998) (2)
- Favorable effects of digoxin on mortality and morbidity in patients with class IV congestive heart failure due to systolic dysfunction: Retrospective analysis of the DIG study (2003) (2)
- Left Ventricular Dysfunction with Pulmonary Hypertension (2)
- Research Acute Heart Failure Syndromes: Current State and Framework for Future (2006) (2)
- The effect of eplerenone on all-cause mortality and heart failure hospitalization in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS) (2004) (2)
- Delay in response to acute myocardial infarction. (1992) (2)
- Time course of dyspnea evolution in the emergency department: results from the URGENT dyspnea survey (2009) (2)
- Medical therapy after acute myocardial infarction. (1991) (2)
- Abstract 2382: The Influence of Electronic Health Records on Quality of Care for Heart Failure (2008) (2)
- Skeletal Muscle Metabolism at Rest and Exercise in Patients with Severe but Compensated Left Ventricular Dysfunction: A 31P Nuclear Magnetic Resonance Study (1991) (2)
- Incomplete versus complete myocardial infarction. (1991) (2)
- Gheorghiade et al Digoxin in the Management of CV Disorders (2004) (2)
- Directions for research in the post-myocardial infarction patient with left ventricular dysfunction. (2008) (2)
- The cardiorenal syndrome: Recognition and treatment (2005) (2)
- Clinical Effectiveness of CRT and ICD Therapy in Men and Women with Heart Failure: Findings from IMPROVE HF (2013) (2)
- Preoperative Noncoronary Cardiovascular Assessment and Management of Kidney Transplant Candidates. (2019) (2)
- The role of digitalis in patients with coronary artery disease. (1984) (2)
- 455 Length of stay for heart failure hospitalization in the eplerenone post‐acute myocardial infarction heart failure efficacy and survival study (EPHESUS) (2004) (2)
- The effect of a pericardial effusion on the shunt across an atrial septal defect. (1989) (2)
- Epidemiology, Prevalence, Treatments, and Clinical Trials (1998) (2)
- EQUITABLE IMPROVEMENT FOR WOMEN AND MEN IN THE USE OF GUIDELINE-RECOMMENDED THERAPIES FOR HEART FAILURE: FINDINGS FROM IMPROVE HF (2010) (2)
- Documentation of QRS Duration and NYHA Class in HF Patients after a Performance Improvement Initiative: IMPROVE HF (2010) (2)
- Nutritional supplementation with amino acids in cardiovascular and metabolic diseases: hypermetabolic syndrome as a therapeutic target. Introduction. (2008) (2)
- 352 Improvement in hyponatremia: insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (2005) (2)
- Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction (2017) (2)
- Reply: To PMID 23273288. (2013) (2)
- Detection of myocardial infarction in heart failure patients with severe left ventricular systolic dysfunction by contrast enhanced MRI (2002) (2)
- Performance matters in heart failure. (2014) (2)
- Reactive oxygen species in heart failure. In: Acute Heart Failure (2008) (2)
- 280 The early assessment of dyspnea in patients with acute heart failure syndromes - the Ularitide Global Evaluation in Acute Decompensated Heart Failure (URGENT) study (2008) (2)
- The role of contrast echocardiography in the differential diagnosis of platypnea (1985) (2)
- Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. (2016) (2)
- An Unmet Need in Heart Failure (2009) (2)
- Effects of vasodilator therapy on survival in patients with chronic heart failure. (1992) (2)
- Acute Cardiac Care: Apocalypse Now! (2006) (2)
- Protein turnover in the failing heart: an ever‐changing landscape (2017) (2)
- Role of β-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. The post-myocardial infarction guideline committee (2003) (2)
- Abstract 3280: Heart Failure Quality of Care in the Outpatient Cardiology Practice Setting: A Report from IMPROVE HF (2007) (2)
- SUBGROUP ANALYSIS OF CLINICAL TRIALS. REPLY (1991) (2)
- The Evolution of Chronic Heart Failure (2002) (2)
- Growth hormone therapy in patients with congestive heart failure: need for further research. (1999) (2)
- Nicardipine in heart failure: distinguishing its acute beneficial from its chronic effects. (1993) (1)
- Abstract 18604: The Prognostic Value of Diuretic Dose in Stable Chronic Heart Failure Patients (2013) (1)
- Heart failure in the new millennium: emerging concepts in its pathophysiology (2000) (1)
- Pre-discharge initiation of carvedilol in patients stabilized during an admission for decompensated heart failure is a safe and effective strategy to improve the use of beta-blocker therapy: results of the IMPACT-HF trial (2003) (1)
- Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial. (2003) (1)
- USE OF NON-AMLODIPINE CALCIUM CHANNEL BLOCKERS IS NOT ASSOCIATED WITH OUTCOMES IN OLDER PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION (2013) (1)
- Acute Heart Failure Assessment: The Role of Focused Emergency Cardiopulmonary Ultrasound in Identification and Early Management (2015) (1)
- Exercise conditioning in elderly patients with heart failure (2000) (1)
- Pharmacologic therapies after myocardial infarction. Discussion (1996) (1)
- Exercise-induced near syncope in a patient with idiopathic hypertrophic subaortic stenosis (1990) (1)
- Abstract 20769: Sudden Cardiac Death Risk After Hospitalization for Heart Failure: Insights From EVEREST (2017) (1)
- Working Group on Emergency Department Management of Acute Heart Failure Research Challenges and Opportunities (1)
- Assessment and treatment of diastolic dysfunction. (1993) (1)
- Women with preserved systolic function have better survival than men: retrospective analysis of the digitalis investigational group (DIG) trial (2004) (1)
- Adverse In-Hospital Outcomes by Systolic Blood Pressure at Admission in Patients Hospitalized With Acute Heart Failure Syndromes–Data from RO AHFS Registry (2012) (1)
- Primary PTCA and thrombolysis for acute myocardial infarction: Observations from the community (1996) (1)
- Recovery of left ventricular function following acute myocardial infarction. (1991) (1)
- Tuesday, 28 August 2012 (2012) (1)
- Acute Heart Failure Syndromes: Highlights from the ESC Working Group on Acute Cardiac Care Meeting Prague, Czech Republic 2006 (2006) (1)
- Acute Heart Failure Syndromes: The Role of Vasopressin Antagonists (2009) (1)
- Influence of Race on Improvements in Use of Guideline Recommended Heart Failure Therapies: Findings from IMPROVE HF (2010) (1)
- Improvement in left ventricular systolic function after pericardiocentesis: case report. (1989) (1)
- Indications for acute and chronic digitalis administration in heart failure. (1986) (1)
- Non-Invasive Estimation of Cardiac Filling Pressures by Residents Using Tissue Doppler Imaging and Handcarried Ultrasound (2007) (1)
- 246 Clinical implications of the QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from the EVEREST program (2008) (1)
- Tolvaptan for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (2011) (1)
- Acute heart failure: nomenclature, pathophysiology, and outcome measures (2005) (1)
- Acute hemodynamic effects of digitalis. (1993) (1)
- Advanced heart failure patients unable to reach ACE inhibitor targets: a high risk population identified during hospitalization (2002) (1)
- Strategies to reduce heart failure readmissions--reply. (2014) (1)
- Measurement of left ventricular ejection fraction using gated 99mTc-sestamibi myocardial planar images: comparison to contrast ventriculography. (1991) (1)
- Digitalis intoxication or intrinsic conduction system disease. (1989) (1)
- Mechanisms, and Future Directions Hydralazine and Isosorbide Dinitrate in Heart Failure : Historical Perspective, (2012) (1)
- Identification and management of risk in patients with coronary and other vascular disease: Foreword (1996) (1)
- Letter by Abu Daya et al Regarding Article, "Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction, Contributions of Collagen and Titin". (2015) (1)
- Digoxin and angiotensin converting enzyme inhibitors in chronic heart failure. (1990) (1)
- NT-proBNP Levels Are Lower in Patients Admitted with Acute Decompensated Heart Failure That Have Metabolic Syndrome Than Those Without (2008) (1)
- Abstract 12886: In-hospital and Early Post-discharge Troponin Elevations Among Patients Hospitalized for Heart Failure: Insights From the ASTRONAUT Trial (2016) (1)
- Reply: Are Changes in Serum Potassium Levels During Admissions for Acute Decompensated Heart Failure Irrelevant for Prognosis: The End of the Story? (2015) (1)
- Clinical Implications of the PR Interval in Patients Hospitalized for Worsening Heart Failure and Reduced Ejection Fraction: Analysis of The EVEREST Study (2014) (1)
- Do Hospitals That Provide Heart Failure Patient Education Prior To Discharge Also Promote Continuity of Care? A Report from OPTIMIZE-HF (2006) (1)
- Corrigendum to ‘Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart’ [Eur J Heart Fail] 2015 August;17(8): 760–763. doi:10.1002/ejhf.315 (2015) (1)
- Biomarkers in Acute Heart Failure Syndromes – Are They Fulfilling Their Promise? (2011) (1)
- Changes in left ventricular function following limited pericardiotomy in a patient with pericardial effusion and shock (1989) (1)
- Combination therapy in heart failure patients: digoxin and an ACE inhibitor (1989) (1)
- Risk of death in patients with preserved systolic function: retrospective analysis of the digitalis investigational group (DIG) trial (2003) (1)
- DIURETIC DOSE AND OUTCOMES AMONG HOSPITALIZED HEART FAILURE PATIENTS: INSIGHTS FROM THE EVEREST TRIAL (2013) (1)
- [Pulmonary edema as a result of pericardial drainage in cardiac tamponade]. (1987) (1)
- Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure (1994) (1)
- The American Journal of Medicine: Introduction (2004) (1)
- Abstract 12794: Hospital Length of Stay and Readmissions Post Heart Failure Hospitalization in the EVEREST Trial (2014) (1)
- Trial finds tolvaptan may help manage congestion in people with heart failure, but did not reduce death or hospitalisation. (2004) (0)
- Potassium and heart failure. (1986) (0)
- MILD ELEVATIONS OF TROPONIN I IN LIVER TRANSPLANT PATIENTS: IS IT A MARKER FOR CONGESTIVE HEART FAILURE?: Abstract# 788 Poster Board #‐Session: P45‐III (2000) (0)
- Novel drugs Mineralocorticoid receptor antagonism : therapeutic potential in acute heart failure syndromes (2011) (0)
- Abstract 12884: Arginine Vasopressin Levels Predict Post-Discharge Morbidity and Mortality in Patients Admitted for Worsening Heart Failure With Reduced Ejection Fraction: Insights From the EVEREST Trial (2011) (0)
- RELATIONSHIP BETWEEN CARDIOLOGY PRACTICE TEACHING STATUS AND IMPROVEMENT IN THE USE OF EVIDENCE-BASED THERAPY FOR HEART FAILURE: FINDINGS FROM IMPROVE HF (2010) (0)
- Predictors of Length of Stay in Patients Hospitalized with Heart Failure: A Report from OPTIMIZE-HF (2007) (0)
- Digitalis and vasodilator therapy for congestive heart failure (1987) (0)
- Establishing the optimal maintenance dose of digoxin (1996) (0)
- Does the Day of the Week Heart Failure Patients Are Admitted Influence Length of Stay or Mortality Risk? Findings from OPTIMIZE-HF (2007) (0)
- Effects of Tolvaptan in Patients Hospitalized with Heart Failure and Renal Impairment and Hypotension in the EVEREST Trial (2008) (0)
- Abstract 13154: Benefit Of Exercise Training Independent Of Heart Failure Severity: The HF-action Experience (2010) (0)
- Abstract P301: Are Variations in Delivery of Guideline Recommended Therapies by Cardiology Practices Reduced After Implementation of a Performance Improvement Initiative? Findings From IMPROVE HF (2011) (0)
- MEDICATION DOSING ADHERENCE IN OUTPATIENTS WITH HEART FAILURE FOLLOWING IMPLEMENTATION OF A PRACTICE-BASED PERFORMANCE IMPROVEMENT INTERVENTION: RESULTS FROM IMPROVE HF (2010) (0)
- Controlled Trial in Patients Hospitalized With Heart Failure a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, (2011) (0)
- Reduces Mortality 0 Days After Randomization Following cute Myocardial Infarction in Patients With eft Ventricular Systolic Dysfunction and Heart Failure (2016) (0)
- Early prosthetic mitral closure due to malfunctioning aortic prosthesis during intra-aortic balloon counterpulsation. (1984) (0)
- BNP Levels in Outpatients with Heart Failure: Frequency of Assessment, Relationship to Symptoms, Disease Severity, and HF Quality of Care Measures (2009) (0)
- 224 Hypothermia: a new predictor of mortality in patients hospitalized with worsening heart failure. Findings from the ACTIV in CHF trial (2005) (0)
- Predictors of In-Hospital Mortality in Patients Presenting with Cardiogenic Shock–Insights from the Romanian Acute Heart Failure Syndromes (RO-AHFS) Registry (2012) (0)
- A Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure: The COMMANDER HF study (2018) (0)
- Abstract 14869: Effects of Atrial Fibrillation on Hospitalizations and Survival in Patients Hospitalized for Systolic Heart Failure: Insights from the ESCAPE Trial. (2010) (0)
- Prevalence of myocardial viability in dysfunctional areas by cardiovascular magnetic resonance in patients with coronary artery disease (2011) (0)
- Reply: effect of ivabradine on early readmissions after hospitalization for worsening heart failure. (2015) (0)
- Tolvaptan-vasopressin Antagonist (2006) (0)
- In response to Nagarajan's letter to the editor “Improvement in ejection fraction—but do not forget the basics, the medications” (2012) (0)
- Nutritional Supplementation with Amino Acids in Ambulatory Patients with Idiophatic Dilatated Cardiomyophaty (2011) (0)
- Introduction: Treatment of Heart Failure: A Managed Care Perspective (1998) (0)
- Identification and management of risk in patients with coronary and other vascular disease. Closing statement. (1996) (0)
- Abstract 12797: Temporal Changes in Mortality Risk Post-Discharge After Hospitalization for Heart Failure (2014) (0)
- Comparison of Medical Treatment in Outpatients Receiving Device Therapy for Systolic Dysfunction: A Report from IMPROVE HF (2008) (0)
- Relationship between Symptomatic Dyspnea and Renal Function in Patients With Acute Heart Failure Syndromes: Results from the URGENT-Dyspnoea Study (Ularitide Global Evaluation in Acute Decompensated Heart Failure) (2010) (0)
- Early Medical Management of Acute Heart Failure Syndromes (2008) (0)
- 1023-111 Effects of Propranolol in Patients with Their First Acute Myocardial Infarction and Persistent Electrocardiographic ST Segment Depression in the Beta Blocker Heart Attack Trial (1995) (0)
- Clinical Characteristics and Outcomes for Hospitalized Heart Failure (HF) Patients with Chronic Obstructive Pulmonary Disease (COPD): Findings from OPTIMIZE-HF (2011) (0)
- Influence of Atrial Fibrillation on the Use of CRT and ICD Therapy in Heart Failure: Findings from IMPROVE HF (2009) (0)
- Variation in HF Quality of Care among US Outpatient Practices: Analysis of 131 Cardiology Practices in IMPROVE HF (2007) (0)
- The management of decompensated heart failure resulting in hospitalization: Proceedings from an expert meeting to review current concepts and to define future directions - Introduction (2003) (0)
- Abstract 2730: Results from the SALT 1 and 2 Trials: Multicenter, Randomized, Placebo-controlled Trials in Patients with Euvolemic and Hypervolemic Hyponatremia (2006) (0)
- The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure. (2013) (0)
- nicardipine, a new calcium channel blocker: a double-blind, placebo-controlled, randomised, repeated cross-over study (2006) (0)
- Predictors of Worsening Renal Function during Hospitalization for Acute Heart Failure Syndromes: Insights from RO-AHFS Registry (2012) (0)
- 35 Regional differences in baseline characteristics and outcomes in patients admitted with acute heart failure - results from the EVEREST program (2008) (0)
- Withdrawal of digoxin after treatment of chronic heart failure led to clinical deterioration and worsening heart failure (1994) (0)
- Accepted Manuscript Characterization of Cardiac Injury During Acute Heart Failure and a Possible Target for Therapy (2014) (0)
- MINERALOCORTICOID RECEPTOR ANTAGONISTS IN DIABETIC PATIENTS HOSPITALIZED WITH HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- Abstract 11413: Serum Aldosterone is Associated with Post-Discharge Events in Patients with Reduced Ejection Fraction Hospitalized for Heart Failure: Analysis from the Everest Trial (2011) (0)
- Abstract 8493: Lack of Association between Discharge Prescription of Aldosterone Antagonists and Outcomes in Medicare Beneficiaries with Heart Failure and Preserved Ejection Fraction: A Propensity-Matched Study of the OPTIMIZE-HF (2011) (0)
- Heart failure / cardiomyopathy Cinaciguat , a soluble guanylate cyclase activator , unloads the heart but also causes hypotension in acute decompensated heart failure † (2012) (0)
- HYPERKALEMIA AFTER HOSPITALIZATION FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: FINDINGS FROM THE ASTRONAUT TRIAL (2018) (0)
- Contents Vol. 40, No. 4, 2015 (2015) (0)
- The Italian study on congestive heart failure in the elderly (2000) (0)
- 1012-126 Contemporary dosing of angiotensin converting enzyme inhibitors and beta blockers in chronic heart failure: Report from the STAMINA:HFP (study of anemia in a heart failure population) registry (2004) (0)
- Rest and stress echocardiography in chronic heart failure (1996) (0)
- Unrecognized Myocardial Infarction (1985) (0)
- 251 Coronary angiography, subsequent use of medical therapy/revascularization, and survival in acute heart failure: a report from OPTIMIZE‐HF (2008) (0)
- Abstract 13559: Gender Does Not Impact Post-Discharge Outcomes in Patients Hospitalized for Worsening Heart Failure with Reduced Ejection Fraction in the EVEREST Trial (2011) (0)
- SERUM MAGNESIUM LEVELS AND POSTDISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR HEART FAILURE: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- Abstract 21224: Coronary Microvascular Dysfunction in Patients With Normal and Abnormal Diastolic Function in Patients With Heart Failure and Preserved Ejection Fraction (2017) (0)
- Impaired renal function is common in outpatients with heart failure: results from the STAMINA-HFP (study of anemia in a heart failure population) registry (2003) (0)
- No effect of amlodipine on mortality or cardiovascular morbidity in patients with severe chronic heart failure. (1997) (0)
- The effects of increasing digoxin dose on rest and exercise fraction exercise tolerance and neurohormones in patients with heart failure on maintenance therapy with digoxin (1992) (0)
- Renal function, independent of ejection fraction and heart size, is a predictor of mortality in patients with heart failure and preserved ejection fraction: a retrospective analysis of the digitalis investigational group (DIG) trial (2004) (0)
- Magnetic resonance imaging provides accurate noninvasive hemodynamic assessment in heart failure: correlation with invasive hemodynamic measurements (2003) (0)
- Abstract 2946: Does Aspirin Use Adversely Influence Intermediate Term Outcomes for Hospitalized Heart Failure Patients Who Are Treated with Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers? Findings from Optimize-HF (2008) (0)
- ASTRONAUT Study: Aliskiren Does Not Improve Postdischarge Outcomes in Patients Hospitalized for Chronic Heart Failure (2013) (0)
- Reply to letter to the editor by Shiraishi and colleagues. (2013) (0)
- HFSA 2006 Comprehensive Heart Failure Practice Guideline HFSA 2006 Comprehensive Heart Failure Practice Guideline (2006) (0)
- Gheorghiade and Ferguson Digoxin 2183 Serum Norepinephrine Levels : Efferent Sympathetic Nerve Activity (2005) (0)
- Wednesday, 29 August 2012 (2012) (0)
- 64 The role of NT-proBNP for detecting asymptomatic left ventricular dysfunction in subjects at risk of heart failure. Results of the PROBE-HF study (2007) (0)
- Risks and benefits of a multidrug approach to mild-to-moderate heart failure. Discussion (2001) (0)
- Response to Letter Regarding Article, “Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspectives, Mechanisms, and Future Directions” (2011) (0)
- Abstract 18059: Clinical Profile and Prognostic Significance of Post-Discharge Hemodilution Among Patients Hospitalized for Heart Failure: Insights From the EVEREST Trial (2017) (0)
- Contemporary Reviews in Cardiovascular Medicine Hydralazine and Isosorbide Dinitrate in Heart Failure Historical Perspective, Mechanisms, and Future Directions (2011) (0)
- Introduction: Managing the patient with advanced heart failure (1998) (0)
- Post-Discharge Adjudicated Outcomes in Patients with Implantable Cardioverter-Defibrillators in the EVEREST Trial (2008) (0)
- FACTORS ASSOCIATED WITH IMPROVEMENT IN GUIDELINE-BASED USE OF IMPLANTABLE CARDIOVERTER DEFIBRILLATORS IN ELIGIBLE HEART FAILURE PATIENTS BY IMPLEMENTING A PRACTICE-BASED PERFORMANCE IMPROVEMENT INTERVENTION: RESULTS FROM IMPROVE HF (2011) (0)
- Outpatient Documentation of NYHA Functional Class and/or Activity Level in HF Patients: A Report from IMPROVE HF (2007) (0)
- Regional Comparison of Baseline Therapy in Patients Hospitalized for Acute Heart Failure with Systolic Dysfunction (2007) (0)
- Adverse In-Hospital Outcomes by Clinical Profile at Admission in Patients Hospitalized With Acute Heart Failure Syndromes–Data from Romanian Acute Heart Failure Syndromes (RO AHFS) Registry (2012) (0)
- and Mihai Gheorghiade Therapies Contemporary Drug Development in Heart Failure : Call for Hemodynamically Neutral (0)
- Reviews and Notes: Cardiology: Calcium Antagonists in Clinical Medicine (1993) (0)
- Abstract 2991: Effect of Rivaroxaban on Biomarkers of Hypercoagulability in Patients With Chronic Heart Failure (2009) (0)
- Inotropes and other new therapies for acute heart failure (2003) (0)
- Treatment of hear failure: A managed care perspective introduction (1998) (0)
- Definitions of Acute Heart Failure Syndromes (2008) (0)
- Hospitalizations for heart failure. Preface. (2013) (0)
- Role of beta-blocker therapy in the postmyocardial infarction patient with and without left ventricular dysfunction consensus guideline. (2003) (0)
- Influence of Advance Practice Nurse and Dedicated Heart Failure Clinics on Delivery of Recommended Therapies in Outpatient Cardiology Practices: IMPROVE HF Findings (2008) (0)
- ST-segment depression and mortality after myocardial infarction (1994) (0)
- Acute Heart Failure Syndromes: Current and Investigational Pharmacotherapeutic Options (2006) (0)
- Novel Therapeutic Concepts Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction : integrating evidence into clinical practice (2012) (0)
- 40: Changes In the Neurohormonal Profile of Patients Hospitalized for Acute Heart Failure Syndromes During the Early Post-Discharge Period According to Early, Late, or No Heart Failure Re-Hospitalization or Mortality Events: Analysis From the EVEREST Trials (2010) (0)
- Initial Therapy Does Not Substantially Improve Dyspnea in Many ER Acute Heart Failure Patients (2012) (0)
- Abstract 21227: Plasma Renin Activity, Response to Aliskiren, and Clinical Outcomes in Patients Hospitalized for Heart Failure: The ASTRONAUT Trial (2017) (0)
- Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure (2002) (0)
- Serial evaluation of left ventricular systolic function in heart failure: The Doppler approach (1991) (0)
- Retraction (2011) (0)
- Trial finds administering carvedilol in hospital improves treatment adherence for people with heart failure. (2004) (0)
- PROGNOSTIC ROLE OF HEMOCONCENTRATION IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: AN ANALYSIS OF THE EVEREST TRIAL (2013) (0)
- IMPROVING HEART FAILURE CARE:Strategies for Increasing Utilization of Beta-Blockade. In-Hospital Initiation of Beta-Blocker Therapy for Heart Failure (2002) (0)
- Reduced hypertension in diabetics after kidney and pancreas transplantation (2002) (0)
- 187: The Effects of Standard Therapy on Dyspnea In Acute Heart Failure Syndromes: Results From the URGENT International Dyspnea Study (2010) (0)
- Correlation of Ejection Fraction to Early Post-Discharge Sudden Death and All-Cause Mortality in The EVEREST Trial (2008) (0)
- Program Patients Hospitalized With Heart Failure: Findings From the OPTIMIZE-HF Influence of Beta-Blocker Continuation or Withdrawal on Outcomes in (2008) (0)
- Symposium on management of heart failure in the 1990s a reassessment of the role of digoxin therapy new york new york usa july 27 28 1991 (1992) (0)
- yocardial Na , K-ATPase : the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure (2002) (0)
- Regional Differences in Baseline Characteristics and Outcomes in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction (2007) (0)
- Left Ventricular Systolic Function and Outcome after Cardiopulmonary Resuscitation in Patients Hospitalized for Acute Heart Failure Syndromes – Data from Romanian Acute Heart Failure Syndromes Study (RO-AHFS Study) (2012) (0)
- Abstract 9871: Utility of Electronic Health Records in Predicting 30-Day Readmission After Heart Failure Hospitalization (2011) (0)
- The QRS Interval Predicts Mortality and Re-Hospitalization in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction (2007) (0)
- Hemodynamic and radionuclide ventriculography changes in response to intravenous captopril and digoxin and their combinations in patients with severe heart failure (1990) (0)
- asopressin Antagonism in Heart Failure (2016) (0)
- The reply. (2014) (0)
- [Morpho-functional assessment of endocardial cushion defect by single crystal and two-dimensional echocardiography (author's transl)]. (1979) (0)
- Prevalence and Characteristics of Prolonged QRS Duration in Outpatients with Left Ventricular Systolic Dysfunction: An IMPROVE HF Analysis (2009) (0)
- Clinical Characteristics and Outcomes of Patients with Ischemic Cardiomyopathy (ICM) and Angina: Findings from the Duke Cardiovascular Database (2011) (0)
- TRENDS IN UTILIZATION OF SURROGATE ENDPOINTS IN CONTEMPORARY CARDIOVASCULAR CLINICAL TRIALS: A SYSTEMATIC REVIEW (2016) (0)
- Clinical Trials: Methods and Design The Rationale for an Acute Heart Failure Syndromes Clinical Trials Network (2009) (0)
- M yocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure (2002) (0)
- Erratum: Heart failure between 1986 and 1994: Temporal trends in drug- prescribing practices, hospital readmissions, anti survival at an academic medical center (American Heart Journal (1997) 134 (pp. 901-9)) (1998) (0)
- Abstract 13323: Chronic Obstructive Pulmonary Disease is Associated with Adverse Events in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: An Analysis of the EVEREST Trial (2011) (0)
- Hospitalized Patients With Heart Failure (OPTIMIZE-HF) Insights From the Organized Program to Initiate Lifesaving Treatment in Predictors of In-Hospital Mortality in Patients Hospitalized for Heart Failure: (2011) (0)
- Abstract 19573: Factors Associated With Improvement in Ejection Fraction in Heart Failure Patients Following Implementation of a Practice-Based Performance Intervention: Findings From IMPROVE HF (2010) (0)
- The Role of Digoxin in Heart Failure (2020) (0)
- Reply: To PMID 23219302. (2013) (0)
- Pathophysiology of heart failure. (1986) (0)
- A suggested new approach to supraventricular tachydysrhythmia after coronary bypass surgery. (1989) (0)
- Abstract 17733: Pulmonary Artery Systolic Pressure by Echocardiography and Outcomes in Stable Outpatients with Heart Failure (2012) (0)
- Systolic blood pressure and outcomes in patients hospitalized with acute heart failure. Authors' reply (2007) (0)
- Effects of Rivaroxaban on Thrombotic Events in Heart Failure Patients With Coronary Disease and Sinus Rhythm (2018) (0)
- 336 The prevalence of asymptomatic left ventricular dysfunction in subjects at risk of heart failure. Results of the PROBE‐HF study (2007) (0)
- Abstract 14223: Atrial Fibrillation, Clinical Outcomes, and Post-discharge Natriuretic Peptide Trajectory Among Patients Hospitalized for Heart Failure: Findings From the ASTRONAUT Trial (2015) (0)
- Hospitalization for Acute Heart Failure Syndromes—Reply (2011) (0)
- 267 Effects of tolvaptan on physician-assessed signs and symptoms in patients admitted with acute heart failure - results from the EVEREST program (2008) (0)
- Analysis of regional left ventricular function by color kinesis in patients with coronary artery disease (1996) (0)
- Prediction of Contractile Improvement in Chronic Heart Failure Patients Treated with Beta-Blocker Therapy (2009) (0)
- Do hemodynamics always predict survival in advanced heart failure? A second look at FIRST (2000) (0)
- [Echocardiography for the evaluation of tricuspid atresia. II. Analysis of the left ventricular function (author's transl)]. (1981) (0)
- Significant Gaps in Adherence to Guideline Recommended Adjunctive Heart Failure Therapies among Outpatient Cardiology Practices: Findings from IMPROVE HF (2008) (0)
- Abstract 13328: Coronary Artery Disease is Associated with a Poor Post-Discharge Prognosis in Patients Hospitalized for Heart Failure with Reduced Ejection Fraction: Findings from the EVEREST Trial (2011) (0)
- Correction (2011) (0)
- Moving Towards a Novel Paradigm in Drug Development for Worsening Heart Failure: The T1 Model (Mechanistic Translational Phase) (2015) (0)
- Rationale and Design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study (2002) (0)
- Special Feature: Management of Acute Myocardial Infarction: Introduction (2020) (0)
- Micronutrient Deficiencies (2010) (0)
- A prospective randomized study of nesiritide versus dobutamine in decompensated heart failure (PRESERVD-HF): design and preliminary data (2003) (0)
- Vasopressin Antagonists in Acute Heart Failure Syndromes (2008) (0)
- Patients with preserved systolic function hospitalized for decompensated heart failure have 60-day event rates similar to patients with systolic dysfunction: observations from the IMPACT-HF registry (2003) (0)
- Clinical severity predicts response to digoxin: a retrospective analysis of the digitalis investigational group (DIG) trial (2004) (0)
- Digoxin and reduction in mortality and hospitalization in systolic and diastolic heart failure at low serum digoxin concentrations: reply (2006) (0)
- Emerging Therapies for HF Target Different Pathophysiology (2014) (0)
- The value of dobutamine stress echo in predicting improvement in left ventricular function in patients with ischemic and nonischemic cardiomyopathy after one year of beta-blocker therapy (2003) (0)
- 183Mild elevations of troponin I in liver transplant patients: Is it a marker for congestive heart failure post-transplant? (2000) (0)
- Are Patient Age and Gender Associated with Delivery of Recommended HF Therapies (2007) (0)
- The heart failure patient (2007) (0)
- [Echocardiography for the evaluation of tricuspid atresia. I. Morphological analysis (author's transl)]. (1981) (0)
- Digoxin in the Management of Cardiovascular Disorders PDATE (2004) (0)
- American Journal of Cardiology: Introduction (2004) (0)
- In-hospital initiation of beta-blocker therapy for heart failure (2002) (0)
- Subject Index Vol. 116, 2010 (2010) (0)
- Is History of Depression a Predictor of In-Hospital Treatment and Early Post-Discharge Outcomes in Patients with Heart Failure? A Report from OPTIMIZE-HF (2007) (0)
- The Use of Non-Invasive Impedance Cardiography (ICG) To Define the Active Dose Range for Invasive Right Heart Hemodynamic Studies – The Istaroxime Experience (2006) (0)
- 1012-104 Safety of beta-blockers in patients with heart failure and renal insufficiency: Data from IMPACT-HF (2004) (0)
- Clinical Investigations Trends in Heart Failure Clinical Trials From 2001e2012 (2016) (0)
- Success of angioplasty for postinfarction angina: Evaluation of left ventricular function (1990) (0)
- Early Medical Management of Hospitalization for Heart Failure (HHF) (2015) (0)
- The American Journal of Cardiolofy: Introduction (2004) (0)
- Risk evaluation at admission of patients with suspected myocardial infarction (1989) (0)
- Current perspectives the cardiorenal syndrome: recognition and treatment. (2005) (0)
- Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES) (2014) (0)
- Pharmacokinetics and pharmacodynamics of rivaroxaban in patients with heart failure (2010) (0)
- Clinical Predictors of Intensive Care Unit Admission in Patients Hospitalized for Pulmonary Edema–Data from the RO-AHFS Registry (2012) (0)
- Abstract 3003: Greater Improvement in Heart Failure Care Quality With a Performance Improvement Initiative is Largely Independent of Patient and Practice Characteristics (2009) (0)
- Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion (2021) (0)
- NON-INFERIORITY DESIGNS OVER THE LAST DECADE OF CONTEMPORARY CARDIOVASCULAR CLINICAL TRIALS (2016) (0)
- Early Assessment and Treatment Acute Heart Failure Syndromes in Patients With Coronary Artery Disease (2009) (0)
- Abstract 20456: Renin-Angiotensin System Inhibition and Reduction in All-Cause Mortality in Medicare Beneficiaries Hospitalized with Acute Diastolic Heart Failure: A Propensity-Matched Study of the OPTIMIZE-HF Registry (2010) (0)
- Changing Clinical Profiles and Timing of Enrollment in Acute Heart Failure Syndromes Clinical Trials (2011) (0)
- Abstract 12208: Mode of Death in Heart Failure With Preserved Ejection Fraction: A Systematic Review (2016) (0)
- Title: Acute Dyspnea and Decompensated Heart Failure Authors (2018) (0)
- QRS Duration in Patients Hospitalized for Worsening Heart Failure--Reply (2008) (0)
- Clinical characteristics, treatment patterns, and 60-day outcomes of patients hospitalized for worsening heart failure: insights from the IMPACT-HF registry (2003) (0)
- Coronary artery disease in heart failure (2002) (0)
- The Authors' reply (2011) (0)
- Introduction to ACCORD-PMI: the Advisory Council on Care Optimization to Reduce Death Post-MI. (2008) (0)
- Elevated B-type natriuretic peptide in patients with asymptomatic aortic regurgitation and normal left ventricular systolic function (2002) (0)
- plerenone Reduces Mortality 0 Days After Randomization Following cute Myocardial Infarction in Patients With eft Ventricular Systolic Dysfunction and Heart Failure (2005) (0)
- Response to the Letter of Hester Den Ruijter and Ruben Coronel Regarding the Article “The Role of n-3 PUFAs in Preventing the Arrhythmic Risk in Patients with Idiopathic Dilated Cardiomyopathy” (2009) (0)
- Design, Feasibility, and Clinical Characteristics of a Novel Heart Failure with Preserved Ejection Fraction Program (2011) (0)
- Abstract 15368: Prognostic Value Of Inflammatory, Extracellular Matrix And Necrosis Biomarkers, And Their Relationship With Neurohormonal Biomarkers And Outcome In Patients With Acute Heart Failure. Data From The Everest Trial (2011) (0)
- INFLUENCE OF URIC ACID LEVEL IN PATIENTS HOSPITALIZED FOR HEART FAILURE WITH REDUCED EJECTION FRACTION: INSIGHTS FROM THE EVEREST TRIAL (2013) (0)
- Heart failure as a manifestation of coronary artery disease (1998) (0)
- Contents Vol. 116, 2010 (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Mihai Gheorghiade?
Mihai Gheorghiade is affiliated with the following schools:
